Lyka Labs

LYKALABS03 May 2024

Pharmaceuticals

₹

-3.45 (-2.82%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Lyka Labs

Lyka Labs

Pharmaceuticals

LYKALABS03 May 2024

₹

-3.45 (-2.82%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
08-Apr-2024	BC	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/04/2024 inter alia to consider and approve to allot and issue 2600000 equity shares upon co	16-Apr-2024
18-Apr-2024	BC	Ipca Laboratories Ltd	16-Apr-2024
16-Jan-2024	BC	Board of Directors of the Company, in its meeting held on 16trh January 2024, has decided to to seek consent of members through postal ballot. The Company has issue postal ballot notice for seekin	22-Feb-2024
18-Jan-2024	BC	Notice of the meeting of equity shareholders to be held as per the order of the honble NCLT Intimation of sending of notices of the meetings of the shareholders and the creditors (As Per BSE An	20-Feb-2024
16-Jan-2024	BC	Pursuant to Reg 30 of the SEBI (LODR) Regulations 2015, the Company has informed that the Board of Directors has approved appointment of Mr. Neeraj Golas as an additional director (Non Executive, Ind	12-Feb-2024

No Rights has been declared by LYKALABS

Book Closure

Record Date	Split Date	Purpose
16-Apr-2024	-	LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/04/2024 inter alia to consider and approve to allot and issue 2600000 equity shares upon co
16-Apr-2024	-	Ipca Laboratories Ltd
22-Feb-2024	01 Jan'1900	Board of Directors of the Company, in its meeting held on 16trh January 2024, has decided to to seek consent of members through postal ballot. The Company has issue postal ballot notice for seekin
20-Feb-2024	-	Notice of the meeting of equity shareholders to be held as per the order of the honble NCLT Intimation of sending of notices of the meetings of the shareholders and the creditors (As Per BSE An
12-Feb-2024	-	Pursuant to Reg 30 of the SEBI (LODR) Regulations 2015, the Company has informed that the Board of Directors has approved appointment of Mr. Neeraj Golas as an additional director (Non Executive, Ind

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Lyka Labs Ltd ₹118.75(-3.45/-2.82%)	118.75	-3.45	392.94	15.80	0.00	3.94
Lupin Ltd ₹1,654.75(+7.10/0.43%)	1,654.75	+7.10	75,415.25	133.18	36.60	3.91
Ipca Laboratories Ltd ₹1,337.70(-13.30/-0.98%)	1,337.70	-13.30	33,938.01	88.94	61.57	5.46
J B Chemicals & Pharmaceuticals Ltd ₹1,889.90(+4.30/0.23%)	1,889.90	+4.30	29,330.27	80.31	57.90	10.92
Sanofi India Ltd ₹8,624.25(-53.50/-0.62%)	8,624.25	-53.50	19,861.65	59.17	33.61	19.54
IOL Chemicals & Pharmaceuticals Ltd ₹395.55(+3.25/0.83%)	395.55	+3.25	2,322.10	-0.40	13.44	1.46

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	31.42	26.76	21.24	19.46	17.13	22.13
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	31.42	26.76	21.24	19.46	17.13	22.13
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.52	0.30	0.43	0.61	1.11	1.04
Total Income	31.94	27.06	21.67	20.07	18.25	23.17
Total Expenditure	25.56	22.87	18.68	16.86	21.81	17.53
PBIDT	6.38	4.19	2.99	3.21	-3.56	5.63
Interest	1.26	1.17	1.33	2.81	3.04	2.91
PBDT	5.12	3.02	1.65	0.39	-6.61	2.72
Depreciation	2.72	3.46	3.34	3.32	3.33	3.46
Tax	0.91	0.10	0.24	-0.35	0.55	0.00
Deferred Tax	0.13	-0.25	-0.20	0.42	-0.27	-0.34
Reported Profit After Tax	1.36	-0.29	-1.72	-3.01	-10.21	-0.40
Extra-ordinary Items	0.00	-0.03	0.00	-0.12	-6.51	-0.14
Adjusted Profit After Extra-ordinary item	1.36	-0.26	-1.72	-2.89	-3.70	-0.26

EPS (Unit Curr.)	0.40	-0.10	-0.54	-1.05	-3.57	-0.15
EPS (Adj) (Unit Curr.)	0.40	-0.10	-0.54	-1.05	-3.57	-0.15
Calculated EPS (Unit Curr.)	0.41	-0.09	-0.52	-0.98	-3.56	-0.14
Calculated EPS (Adj) (Unit Curr.)	0.41	-0.09	-0.52	-0.98	-3.56	-0.14
Calculated EPS (Ann.) (Unit Curr.)	1.65	-0.35	-2.08	-3.92	-14.24	-0.55
Calculated EPS (Adj) (Ann.) (Unit Curr.)	1.65	-0.35	-2.08	-3.92	-14.24	-0.55
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	33.09	33.09	33.09	30.69	28.69	28.69
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	20.31	15.66	14.08	16.50	-20.78	25.44
PBDTM(%)	16.30	11.29	7.77	2.00	-38.59	12.29
PATM(%)	4.33	-1.08	-8.10	-15.47	-59.60	-1.81

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	32.56	27.99	22.88	22.24	17.82	25.53
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	32.56	27.99	22.88	22.24	17.82	25.53
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.54	0.25	0.38	0.43	1.06	1.19
Total Income	33.11	28.23	23.25	22.67	18.88	26.72
Total Expenditure	25.70	24.24	20.23	19.35	22.61	20.70
PBIDT	7.41	3.99	3.02	3.31	-3.73	6.01
Interest	1.28	1.19	1.35	2.85	3.08	3.03
PBDT	6.13	2.80	1.67	0.47	-6.82	2.98
Depreciation	2.84	3.59	3.47	3.47	3.47	3.62
Minority Interest Before NP	0.23	-0.13	-0.08	0.01	-0.11	0.04
Tax	1.04	0.14	0.34	-0.35	0.55	0.00
Deferred Tax	0.23	-0.32	-0.21	0.35	-0.32	-0.30
Reported Profit After Tax	1.78	-0.49	-1.85	-3.01	-10.42	-0.38
Minority Interest After NP	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit after Minority Interest	1.78	-0.49	-1.85	-3.01	-10.42	-0.38

Extra-ordinary Items	0.00	-0.34	0.00	-0.36	-6.63	-0.21
Adjusted Profit After Extra-ordinary item	1.78	-0.15	-1.85	-2.65	-3.79	-0.17

EPS (Unit Curr.)	0.53	-0.15	-0.57	-1.05	-3.64	-0.14
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	33.09	33.09	33.09	30.69	28.69	28.69

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	22.76	14.26	13.20	14.88	-20.93	23.54
PBDTM(%)	18.83	10.00	7.30	2.11	-38.27	11.67
PATM(%)	5.47	-1.75	-8.09	-13.53	-58.47	-1.49

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	31.77	29.47	29.40	29.33	29.04	29.01
Reserves Total	28.30	15.75	-24.28	-9.91	69.71	67.89
Equity Share Warrants	17.44	0.00	0.00	0.00	0.76	0.76
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	77.51	45.22	5.12	19.42	99.51	97.66
Secured Loans	3.34	3.78	151.37	126.88	78.03	89.73
Unsecured Loans	70.02	124.49	10.58	9.35	12.41	11.05
Total Debt	73.36	128.27	161.95	136.23	90.44	100.78
Total Liabilities	150.87	173.49	167.07	155.65	189.95	198.44
APPLICATION OF FUNDS :
Gross Block	153.59	171.88	162.94	140.52	93.40	94.27
Less : Accumulated Depreciation	88.07	81.76	67.60	38.87	17.17	13.11
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	65.52	90.12	95.34	101.65	76.23	81.16
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	16.23	17.74	24.40	26.40	29.71	26.43
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	32.41	32.41	32.41	32.41	62.46	62.45
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	6.94	8.18	4.30	5.71	5.95	7.30
Sundry Debtors	17.16	17.59	9.90	6.59	29.68	30.26
Cash and Bank	8.70	15.38	6.53	8.40	0.09	0.47
Loans and Advances	9.49	6.03	5.00	9.99	13.30	15.21
Total Current Assets	42.29	47.19	25.73	30.69	49.02	53.24
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	19.84	25.24	32.46	42.24	54.24	41.90
Provisions	1.17	1.02	1.62	1.91	1.51	1.62
Total Current Liabilities	21.01	26.25	34.08	44.15	55.75	43.52
Net Current Assets	21.28	20.93	-8.35	-13.46	-6.73	9.72
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.00	0.00	16.22	12.28	10.41	1.68
Deferred Tax Liability	3.99	4.12	0.00	0.00	0.16	0.27
Net Deferred Tax	-3.99	-4.12	16.22	12.28	10.25	1.41
Total Assets	131.45	157.08	160.01	159.28	171.92	181.17
Contingent Liabilities	23.10	31.00	20.56	28.00	0.00	0.00

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	31.77	29.47	29.40	29.33	29.04	29.01
Reserves Total	-2.69	-15.35	-54.49	-43.03	14.12	20.57
Equity Share Warrants	17.44	0.00	0.00	0.00	0.76	0.76
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	46.52	14.12	-25.09	-13.70	43.92	50.34
Minority Interest	0.23	0.15	0.70	-0.77	2.74	3.36
Secured Loans	4.01	5.17	151.95	130.90	82.09	99.23
Unsecured Loans	70.02	124.49	10.68	9.77	13.44	12.57
Total Debt	74.03	129.66	162.63	140.67	95.53	111.80
Policy Holders Fund	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	3.37	6.05	13.58	22.86	6.03	4.30
Total Liabilities	124.15	149.98	151.82	149.06	148.22	169.80
APPLICATION OF FUNDS :
Gross Block	157.96	177.35	202.50	188.37	202.81	155.31
Less: Accumulated Depreciation	89.87	83.40	104.31	83.58	95.08	39.27
Less: Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	68.09	93.95	98.19	104.79	107.73	116.04
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	16.23	17.74	25.76	27.76	31.07	27.88
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.05	0.02	0.02	0.02	0.02	0.23
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	6.95	8.20	4.31	6.73	7.00	11.20
Sundry Debtors	20.13	18.45	8.67	8.04	14.63	20.50
Cash and Bank	11.71	17.05	7.15	10.30	1.71	2.43
Loans and Advances	5.40	8.49	8.94	10.79	11.76	14.94
Total Current Assets	44.20	52.19	29.07	35.87	35.10	49.06
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	22.16	30.36	36.49	48.88	65.65	54.67
Provisions	1.20	1.05	1.70	2.23	2.02	4.72
Total Current Liabilities	23.37	31.40	38.19	51.10	67.67	59.38
Net Current Assets	20.83	20.79	-9.12	-15.24	-32.57	-10.32
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.00	0.00	16.35	12.29	13.41	4.24
Deferred Tax Liability	4.01	4.23	0.00	0.00	0.38	0.28
Net Deferred Tax	-4.01	-4.23	16.35	12.29	13.03	3.96
Other Assets	22.96	21.71	20.63	19.46	28.94	32.01
Total Assets
Contingent Liabilities	23.90	31.44	43.97	28.00	0.50	0.00

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	15.38	6.53	8.40	0.12	0.47
Net Cash from Operating Activities	6.87	76.53	5.75	-11.45	18.31
Net Cash Used In Investing Activities	6.77	-4.33	0.13	0.13	-2.94
Net Cash Used In Financing Activities	-20.33	-63.35	-7.75	19.61	-15.76
Net Inc./Dec In Cash And Cash Equivalents	-6.69	8.85	-1.88	8.28	-0.38
Cash And Cash Equivalents At End Of The Year	8.70	15.38	6.53	8.40	0.09

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

58.10%

FII Shareholding

0.16%

DII Shareholding

0.82%

Public Shareholding

40.92%

**Promoter pledged shareholding 58.10%

About Lyka Labs Ltd

Lyka Labs Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 392.12 crores. It has reported a sales of Rs. 31.42 crores and a net profit of Rs. 1.36 crores for the quarter ended December 2018. The company management includes KUNAL NARENDRA GANDHI, KUNAL NARENDRA GANDHI,Sandeep P Parikh,Yogesh B Shah,Dhara P. Shah,Kishore P Shah,Babulal Jain,Prashant Godha,Shashil Mendonsa (Lyka Labs Ltd) among others.

Chairman

KUNAL NARENDRA GANDHI

Registered office

4801/B & 4802/A,GIDC Industrial Estate,Ankleshwar,Gujarat,393002

FAX :91-02646-250692

Background

Incorporation Year1976

Face Value₹10

Market Lot1

How to buy Lyka Labs shares on nse?

To buy Lyka Labs shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Lyka Labs share price today?

The Lyka Labs shares price on nse is Rs.118.75 today.

What is the market cap of Lyka Labs shares on NSE ?

The company has a market capitalization of Rs.392.94Cr

What is the PE & PB ratio of Lyka Labs shares ?

PE is 0 and PB is 3.94

What is the 52 Week High and Low of Lyka Labs shares?

Lyka Labs stock price high: Rs.144.3 Lyka Labs stock price low: Rs.88.5